Alzheimer's Disease Life Course Perspectives on Risk Reduction
Auteurs : Borenstein Amy, Mortimer James
Alzheimer's Disease: Lifecourse Perspectives on Risk Reduction summarizes the growing body of knowledge on the distribution and causes of Alzheimer?s disease (AD) in human populations, providing the reader with knowledge on how we define the disease and what its risk and protective factors are in the context of a life-course approach.
At the conclusion of the book, the reader will understand why Alzheimer?s disease likely begins at conception, then progresses through early-life and adult risk factors that ultimately impact the balance between pathologic insults in the brain and the ability of the brain to modify disease symptoms. In contrast to edited volumes that may have little cohesion, this book focuses on an integrated life-course approach to the epidemiology of dementia, in particular, Alzheimer?s disease.
Prologue: A Primer on Epidemiologic Concepts and MethodsSection 1. Defining a CaseChapter 1. The "First" CaseChapter 2. Clinical Appearance, Progression, and ClassificationChapter 3. Epidemiologic Definition of a CaseChapter 4. Neuropathology of Alzheimer's DiseaseChapter 5. The Threshold Model of DementiaSection 2. Descriptive EpidemiologyChapter 6. The Prevalence of Alzheimer's DiseaseChapter 7. The Incidence of Alzheimer's DiseaseChapter 8. Survival and Mortality in Alzheimer's DiseaseSection 3. Analytic EpidemiologyChapter 9. Introduction to the Analytic Epidemiology of Azheimer's DiseaseChapter 10. Family History, Genetics, and Down Syndrome Chapter 11. Early-Life FactorsChapter 12. Traumatic Brain InjuryChapter 13. Gigarette Smoking and Alcohol ConsumptionChapter 14. Vascular DiseaseChapter 15. DietChapter 16. Physical ActivityChapter 17. Cognitive ActivityChapter 18. Social EngagementChapter 19. Non-Steroidal Anti-Inflammatory Drugs, Hormone Replacement Therapy, and Anticholinergic MedicationsSection 4. Epidemiologic and Biologic MarkersChapter 20. Prodromal Markers of Disease or Causal Risk Factors? Depression, Olfaction, and Subjective Memory ComplaintsChapter 21. Fluid, Imaging, and Cognitive Biomarkers
Section 5. Future StepsChapter 22. Risk Assessment and Prevention of Alzheimer's DiseaseChapter 23. Summary and Recommendations
Dr. James A. Mortimer is a pioneer in the field of Alzheimer’s disease and the first scientist to conduct a systematic case-control study of the causes of the disease. He has devoted his professional life to the study of Alzheimer’s and Parkinson’s disease, and is nationally and internationally recognized as one of the leading researchers in the field of Alzheimer’s disease epidemiology. His work in the Nun Study led to the discovery that characteristics of language at age 20 predicted the risk for Alzheimer’s 60 years later, suggesting that the origins of the disease date to early life. In 1994, Dr. Mortimer was the Executive Convener of the Fourth International Conference on Alzheimer's Disease. He is the editor of four books, including the Epidemiology of Dementia published in 1981.
- Reviews the current science surrounding Alzheimer’s disease
- Provides a primer of foundational knowledge on the disease's epidemiology and biostatistics
- Utilizes a life-course approach, providing a novel and integrated view of the evolution of this illness from genes to brain reserve
- Uses the ‘threshold model’—a theory first described by Dr. Mortimer and widely accepted today—which incorporates the idea of risk factors for the pathology and expression of the disease
- Proposes that improving brain health through modifiable behaviors can delay disease onset until a later age
- Examines the future of prevention of Alzheimer’s disease, a subject of great current interest
Date de parution : 02-2016
Ouvrage de 466 p.
15x22.8 cm
Thème d’Alzheimer's Disease :
Mots-clés :
-carotene; Additive and multiplicative interaction; Aerobic exercise; Age; Alcohol consumption; Alcoholic dementia; Alzheimer's disease; Animal studies; Anticholinergic medications; Apolipoprotein E; Atrophy; B vitamins; BDNF polymorphism; Biomarkers; Birth order; Birth weight; Braak staging; Brain reserve; Brain volume; Brain weight; Brain-derived neurotrophic factor; CSF; Caloric restriction; Case definition; Case definition and detection; Case detection; Case-control studies; Causal risk factors; Cause of death; Cerebral amyloid angiopathy; Cholesterol; Chronic traumatic encephalopathy; Cigarette smoking; Clinical course; Clinical description; Clinical research criteria; Clinical signs and symptoms; Clinicopathologic studies; Cognitive activities; Cognitive biomarkers; Cognitive reserve; Cognitive training; Cohort studies; Combinations of biomarkers; Competing causes; Costs; Critical time windows for intervention; Critical window hypothesis; Cumulative lifetime risk; D; Death certificates; Dementia; Dementia threshold; Demographic trends; Depression; Diabetes; Diet; Dietary patterns; Down syndrome; Dr Alois Alzheimer; Drug prevention trials; E; Early-life body growth; Early-life brain development; Early-life socioeconomic status; Education; Family history; Family studies; Fats; Fertility; Fibrillar amyloid PET; Fish; Fluorodeoxyglucose PET; Folate; Fruits and vegetables; Functional MRI; Future design of cohort studies; Genetic mutations; Genetic polymorphisms; Genome-wide association studies; Head circumference; Heritability; Homocysteine; Hormone replacement therapy; Hypertension; IQ; Idea density; Incidence; Intracranial volume; Lacunar infarcts; Lewy bodies; Life course; Lifelong prevention; Literacy; Living alone; Loneliness; Marriage; Maternal age; Mechanisms
